IONIS PHARMACEUTICALS INC — Form 8-K
Filed October 21, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
GSK announced FDA approval of Hibsago (bepirovirsen) on October 20, 2026, for chronic hepatitis B treatment in adults without cirrhosis. The Phase 3 B-Well trials showed 19% functional cure rate (233 of 1,220 patients) versus 0% in placebo, and 26% in the subgroup with lower baseline HBsAg levels (200 of 768). Under the 2019 licensing agreement, Ionis receives tiered royalties of 10-12% on net sales plus eligible regulatory and sales milestone payments.
Why this rating
FDA approval validates flagship asset; meaningful royalty stream (10-12%) on a 1.7M-patient U.S. market. Represents ~1.4% of company's $5.3B market cap if conservatively valued, but transformative for hepatitis B franchise and validates Ionis' RNA platform.
Price action (we called it positive)
before filing · preread $44.99 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 21, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.